Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples